Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability.

ABSTRACT: Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory or autoimmune diseases. We assessed the effects of ruxolitinib on lipopolysaccharide (LPS)- and poly (I:C)-induced cytokine production by human lung macrophages (LMs) and on the LMs' phagocytic activity. Methods: Human LMs were isolated from patients operated on for lung carcinoma. The LMs were cultured with ruxolitinib (0.5 × 10^-7 M to 10^-5 M) or budesonide (10^-11 to 10^-8 M) and then stimulated with LPS (10 ng·ml^-1) or poly (I:C) (10 μg·ml^-1) for 24 h. Cytokines released by the LMs into the supernatants were measured using ELISAs. The

SUBMITTER: Mantov N 

PROVIDER: S-EPMC9437255 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature